Full text

Turn on search term navigation

Copyright © 2022 Ziyan Wang et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0/

Abstract

By employing nuclear magnetic resonance (NMR), we implemented a chemical research on Shuanghuanglian injection (SHLI) and identified 17 components, including eight primary metabolites and nine secondary metabolites. Guided by the approach of network pharmacology, the potential activities were briefly predicted for seven primary metabolites except for formic acid, such as anti-inflammation, antioxidation, and cardiovascular protection. The focused primary metabolites were quantified by a proton nuclear magnetic resonance (1H-NMR) method, which was verified with good linearity and satisfactory precision, repeatability, stability, and accuracy (except for myo-inositol with mean recovery at 135.78%). Based on the successfully established method, seven primary metabolites were effectively quantified with a slight fluctuation in 20 batches of SHLIs. The average total content of these compounds was 6.85 mg/mL, accounting for 24.84% in total solid of SHLI. This research provides an alternative method for analysis of primary metabolites and contributes to the quality control of SHLI.

Details

Title
Qualitative and Quantitative Evaluation of Chemical Constituents from Shuanghuanglian Injection Using Nuclear Magnetic Resonance Spectroscopy
Author
Wang, Ziyan 1 ; Wang, Zuoyuan 1 ; Jiang, Miaomiao 1 ; Yang, Jing 1 ; Meng, Qingfen 2 ; Guan, Jianli 2 ; Xu, Maoling 3   VIAFID ORCID Logo  ; Chai, Xin 1   VIAFID ORCID Logo 

 State Key Laboratory of Component-based Chinese Medicine, Tianjin Key Laboratory of TCM Chemistry and Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China 
 Henan Fusen Pharmaceutical Co.,Ltd., Henan 474450, China 
 Tianjin Medical University General Hospital, Tianjin 300052, China 
Editor
Ilari Filponnen
Publication year
2022
Publication date
2022
Publisher
John Wiley & Sons, Inc.
ISSN
20908865
e-ISSN
20908873
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2640854931
Copyright
Copyright © 2022 Ziyan Wang et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0/